302
Participants
Start Date
October 25, 2017
Primary Completion Date
January 14, 2022
Study Completion Date
January 3, 2025
isatuximab SAR650984
"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
carfilzomib
"Pharmaceutical form: solution for infusion~Route of administration: intravenous"
dexamethasone
"Pharmaceutical form: tablets or solution for infusion~Route of administration: oral or intravenous"
Investigational Site Number : 3480003, Budapest
Investigational Site Number : 3480001, Budapest
Investigational Site Number : 3480004, Budapest
Investigational Site Number : 5540001, Auckland
Investigational Site Number : 0360005, Blacktown
Investigational Site Number : 0360006, Tweed Heads
Investigational Site Number : 0360002, Wollongong
Investigational Site Number : 0360001, Fitzroy
Investigational Site Number : 0360004, Heidelberg West
Investigational Site Number : 0360008, West Perth
Investigational Site Number : 0360007, Nedlands
Investigational Site Number : 5540002, Wellington
Investigational Site Number : 3480005, Kaposvár
Investigational Site Number : 3800002, Torino
Investigational Site Number : 3000002, Athens
Investigational Site Number : 3000005, Athens
Investigational Site Number : 3000001, Athens
Investigational Site Number : 2030001, Prague
Investigational Site Number : 7920005, Bursa
Investigational Site Number : 3000004, Pátrai
Investigational Site Number : 7240003, Madrid
Investigational Site Number : 2500002, Pessac
Investigational Site Number : 7920002, Istanbul
Investigational Site Number : 3800003, Bologna
Investigational Site Number : 7240004, Seville
Investigational Site Number : 3800004, Reggio Emilia
Investigational Site Number : 2500001, Nantes
Investigational Site Number : 7240002, Valencia
Investigational Site Number : 7920004, Samsun
Investigational Site Number : 3800001, Pisa
Investigational Site Number : 3000003, Thessaloniki
Investigational Site Number : 2500003, Lille
Investigational Site Number : 2030002, Brno
Investigational Site Number : 2500005, Pierre-Bénite
Investigational Site Number : 2030003, Ostrava - Poruba
Investigational Site Number : 2500006, Paris
Investigational Site Number : 2030004, Olomouc
Investigational Site Number : 2500004, Poitiers
UCSF MS Center Site Number : 8400002, San Francisco
Investigational Site Number : 6430003, Kirov
Investigational Site Number : 6430002, Yekaterinburg
Investigational Site Number : 6430004, Novosibirsk
Spartanburg Medical Center Site Number : 8400003, Spartanburg
Hospital Sao Rafael - Rede D'OR Sao Luiz Site Number : 0760005, Salvador
Hospital Mae de Deus Site Number : 0760003, Porto Alegre
Hospital de Amor - Hospital do Cancer de Barretos - Fundacao Pio XII Site Number : 0760001, Barretos
Hospital das Clinicas de Sao Paulo Site Number : 0760002, São Paulo
Instituto COI de Educacao e Pesquisa Site Number : 0760004, Rio de Janeiro
Investigational Site Number : 1240003, Surrey
Investigational Site Number : 1240001, Saint John
Investigational Site Number : 1240002, Montreal
Investigational Site Number : 3920005, Shiwa-gun
Investigational Site Number : 3920007, Kumamoto
Investigational Site Number : 3920001, Suwa-shi
Investigational Site Number : 3920003, Sunto-gun
Investigational Site Number : 3920004, Shibuya-ku
Investigational Site Number : 3920006, Shinjuku-ku
Investigational Site Number : 3920002, Yamagata
Investigational Site Number : 4100006, Busan
Investigational Site Number : 4100002, Gangnam-gu
Investigational Site Number : 4100001, Seoul
Investigational Site Number : 4100004, Seoul
Investigational Site Number : 4100005, Seoul
Investigational Site Number : 7240001, Badalona
Investigational Site Number : 7240005, Barcelona
Investigational Site Number : 7920003, Adana
Investigational Site Number : 7920001, Ankara
Investigational Site Number : 8260004, Plymouth
Investigational Site Number : 8260005, Leicester
Investigational Site Number : 8260001, Bristol
Lead Sponsor
Sanofi
INDUSTRY